New pill for advanced cancers with TP53 Y220C mutation
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new pill called JAB-30355 for people with advanced cancers that have a specific genetic change (TP53 Y220C). It's for those who have already tried other treatments and are looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a specific genetic change in your tumor called TP53 Y220C (your doctor can check this).
- You must have had at least one prior cancer treatment that didn't work or stopped working.
- Your cancer must be measurable on scans (like a CT scan).
- You must be able to swallow pills and have good organ function (kidneys, liver, blood counts).
- You cannot have cancer that has spread to your brain or spinal cord, or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
This trial tests a new drug, GenSci128, for people whose solid tumors have a specific TP53 Y220C mutation. The drug aims to reactivate the p53 protein to fight cancer. It is for patients who have exhausted standard treatments.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
This trial tests an experimental pill (JAB-23E73) for people with advanced solid tumors that have a specific KRAS gene change. It aims to see if the drug can shrink or slow the growth of these cancers.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.